A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate

被引:0
|
作者
Kunogi, Hiroaki [1 ,2 ]
Cunha, Jason Adam M. [1 ]
Chang, Albert J. [1 ]
Gadzinski, Adam J. [3 ]
Shinohara, Katsuto [3 ]
Hsu, I-Chow [1 ]
机构
[1] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Divisadero St,H1031, San Francisco, CA 94143 USA
[2] Juntendo Univ, Dept Radiat Oncol, Bunkyo Ku, Tokyo, Japan
[3] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA
关键词
Brachytherapy; HDR; Prostate; TURP; Urinary catheter; CANCER; RADIOTHERAPY; TOXICITY;
D O I
10.1016/j.brachy.2017.07.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: The purpose of this study was to assess retrospectively the variability of the urethral dose optimized using a Foley catheter versus urethral contrast injected using a new modified triple-lumen catheter, in CT-based high-dose-rate (HDR) prostate brachytherapy of posttransurethral resection of prostate (TURP) patients. METHODS AND MATERIALS: At our institution, there were six post-TURP patients with prostate carcinoma between July 2014 and April 2016 who underwent transperineal interstitial HDR brachytherapy (16 needles). A custom modified triple-lumen catheter was placed to inject contrast into the TURP defect. Three-dimensional optimal plans using inverse planning simulated annealing algorithm was generated according to radiation therapy oncology group dose requirements. Alternative plans were retroactively generated for comparison using standard technique based on a Foley catheter as a urethral constraint volume for each patient with the same weighting factors. We compared the dosimetry parameters in each planning using Wilcoxon's ranked sum nonparametric test. RESULTS: The median followup of all patients was 17.5 months. No significant genitourinary or gastrointestinal toxicity was noted using this technique. In the dosimetric analysis, the prostate V-100 values and TURP urethral V100 were significantly different between plans with and without the contrast (V100 [mean]: 92.4 [%] vs. 94.4 [%], p = 0.046; TURP UV100 [mean]: 1.4 cc vs. 2.2 cc, p = 0.028). There were no statistical differences in the mean values of planning target volume V-150%, V(20)0%, and D-90, and each bladder V-75 and rectum (V75). CONCLUSIONS: Post-TURP HDR brachytherapy with urethral contrast showed significantly more volume effect of the TURP defect than that with a Foley catheter alone. Better visualization of the TURP defect should lead to more accurate urethral sparing administration of HDR brachytherapy which is necessary to prevent urethral complication. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 50 条
  • [1] Genitourinary Toxicity In Prostate Cancer Patients With History Of Transurethral Resection Of The Prostate Undergoing High Dose Rate Brachytherapy With A Novel Urethral-Sparing Technique
    Chew, J.
    Wong, A. C.
    Shinohara, K.
    Roach, M., III
    Hsu, I. C. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E904 - E904
  • [2] A novel direction modulated brachytherapy technique for urethra sparing in high-dose-rate brachytherapy of prostate cancer
    Meftahi, Moeen
    Qiu, Richard Lei Jingyi
    Patel, Pretesh
    Song, William Youngjae
    Yang, Xiaofeng
    RADIOTHERAPY AND ONCOLOGY, 2023, 186
  • [3] A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy
    Lu, Diana J.
    Phillips, Tiffany
    DeMarco, John
    Sandler, Howard M.
    Kamrava, Mitchell
    BRACHYTHERAPY, 2020, 19 (02) : 216 - 221
  • [4] Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer
    Luo, Hao Lun
    Fang, Fu Min
    Chuang, Yao Chi
    Chiang, Po Hui
    BJU INTERNATIONAL, 2009, 104 (11) : 1620 - 1623
  • [5] High-dose-rate brachytherapy as monotherapy for prostate cancer
    Demanes, D. Jeffrey
    Ghilezan, Michel I.
    BRACHYTHERAPY, 2014, 13 (06) : 529 - 541
  • [6] Developing a High-Dose-Rate Prostate Brachytherapy Program
    Waring, Jayne
    Gosselin, Tracy
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (02) : 199 - 205
  • [7] High-dose-rate brachytherapy as monotherapy in prostate cancer
    Rebecca Kelsey
    Nature Reviews Urology, 2015, 12 (7) : 359 - 359
  • [8] High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
    Yoshioka, Yasuo
    Suzuki, Osamu
    Otani, Yuki
    Yoshida, Ken
    Nose, Takayuki
    Ogawa, Kazuhiko
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2014, 6 (01) : 91 - 98
  • [9] PREVIOUS TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IS NOT A CONTRAINDICATION FOR INTERSTITIAL HIGH DOSE RATE (HDR) BRACHYTHERAPY FOR PROSTATE CANCER
    Manning, S.
    Mark, R.
    Anderson, P.
    Akins, R.
    Nair, M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S412 - S413
  • [10] Previous Transurethral Resection of the Prostate (TURP) is not a Contraindication for Interstitial High Dose Rate (HDR) Brachytherapy for Prostate Cancer
    Manning, M.
    Mark, R. J.
    Anderson, P. J.
    Akins, R. S.
    Nair, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S371 - S371